Research & Literature

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

Roschewski M, Dunleavy K, Pittaluga S, et al.

The Lancet. Oncology 2015; (16(5)):541-9.

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

Kurtz DM, Green MR, Bratman SV, et al.

Blood 2015; (125(24)):3679-87 doi:10.1182/blood-2015-03-635169.

Malignant lymphoma of the conjunctiva.

Kirkegaard MM, Coupland SE, Prause JU, Heegaard S

Survey of ophthalmology 2015; (60(5)):444-58.

Treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma.

Fabbri A, Cencini E, Bocchia M

Cancer 2015; (121(20)):3746-7 doi:10.1002/cncr.29509.

Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.

Adams HJ, Nievelstein RA, Kwee TC

Blood reviews 2015; (29(6)):417-25.

Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray.

Lunning MA

Oncology (Williston Park, N.Y.) 2015; (29(8)):545-50.

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Bishton MJ, Hughes S, Richardson F, et al.

British journal of haematology 2016; (172(2)):246-54 doi:10.1111/bjh.13831.

[Lymphomas].

Lohri A

Praxis 2016; (105(1)):47-52 doi:10.1024/1661-8157/a002237.

Primary bone lymphoma with multifocal osteolytic lesions: a rare case report with review of literature.

Mandal PK, Baul S, Dolai TK

Blood research 2015; (50(4)):256-60 doi:10.5045/br.2015.50.4.256.

Evaluation of peripheral lymphadenopathy with excisional biopsy: six-year experience.

Özkan EA, Göret CC, Özdemir ZT, et al.

International journal of clinical and experimental pathology 2015; (8(11)):15234-9.

Current challenges and novel treatment strategies in double hit lymphomas.

Anderson MA, Tsui A, Wall M, et al.

Therapeutic advances in hematology 2016; (7(1)):52-64 doi:10.1177/2040620715608091.

Conjunctival Lymphoma--An International Multicenter Retrospective Study.

Kirkegaard MM, Rasmussen PK, Coupland SE, et al.

JAMA ophthalmology 2016; (134(4)):406-14 doi:10.1001/jamaophthalmol.2015.6122.

Non-Hodgkin lymphoma in Southern Africa: review of 487 cases from The International Non-Hodgkin Lymphoma Classification Project.

Perry AM, Perner Y, Diebold J, et al.

British journal of haematology 2016; (172(5)):716-23 doi:10.1111/bjh.13885.

Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.

Bhatt VR

Current hematologic malignancy reports 2016; (11(3)):196-207 doi:10.1007/s11899-016-0319-0.

Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database.

Conte C, Rueter M, Laurent G, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016; (24(11)):4791-9 doi:10.1007/s00520-016-3331-y.

Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".

Bauml JM, Troxel A, Epperson CN, et al.

Lung cancer (Amsterdam, Netherlands) 2016; (100()):110-113 doi:10.1016/j.lungcan.2016.08.002.

High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.

Rosenthal A, Younes A

Blood reviews 2017; (31(2)):37-42 doi:10.1016/j.blre.2016.09.004.

Non-Hodgkin lymphoma.

Armitage JO, Gascoyne RD, Lunning MA, Cavalli F

Lancet (London, England) 2017; (390(10091)):298-310 doi:10.1016/S0140-6736(16)32407-2.

Cyclophosphamide and Doxorubicin Induced Melanonychia: A Case Report.

Prajapati VB, Madhyastha S, Acharya R, et al.

Journal of clinical and diagnostic research : JCDR 2017; (11(1)):OD04-OD05 doi:10.7860/JCDR/2017/23041.9216.

A cyclin D1-positive diffuse large B-cell lymphoma of germinal center B-cell-like subtype in the right tonsil: A rare case report.

Jiang C, Shi X, Fan C

Medicine 2017; (96(11)):e6311 doi:10.1097/MD.0000000000006311.

The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.

Yang Y, Wang L, Ma Y, et al.

The American journal of the medical sciences 2017; (353(5)):459-465 doi:10.1016/j.amjms.2017.02.002.

Novel Insights into Membrane Targeting of B Cell Lymphoma.

de Winde CM, Elfrink S, van Spriel AB

Trends in cancer 2017; (3(6)):442-453 doi:10.1016/j.trecan.2017.04.006.

Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.

Maeda Y, Nishimori H, Yoshida I, et al.

Haematologica 2017; (102(12)):2097-2103 doi:10.3324/haematol.2017.167742.

Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Miyaoka M, Kikuti YY, Carreras J, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(2)):313-326 doi:10.1038/modpathol.2017.134.

Different manifestation of irradiation induced coronary artery disease detected with coronary computed tomography compared with matched non-irradiated controls.

van Rosendael AR, Daniëls LA, Dimitriu-Leen AC, et al.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2017; (125(1)):55-61 doi:10.1016/j.radonc.2017.09.008.

Head and Neck Lymphoma in an Iranian Population.

Shamloo N, Ghannadan A, Jafari M, et al.

Iranian journal of otorhinolaryngology 2017; (29(94)):261-267.

Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.

Myers RM, Hill BT, Shaw BE, et al.

Cancer 2018; (124(4)):816-825 doi:10.1002/cncr.31114.

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Eskelund CW, Albertsson-Lindblad A, Kolstad A, et al.

Haematologica 2018; (103(11)):e541-e543 doi:10.3324/haematol.2018.194399.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Eyre TA, Walter HS, Iyengar S, et al.

Haematologica 2019; (104(2)):e68-e71 doi:10.3324/haematol.2018.198812.

Antiphospholipid antibodies associated with nodal marginal zone lymphoma and its progression to diffuse large B-cell lymphoma-A case report.

Belančić A, Vranić L, Ševeljević I, et al.

Pathology, research and practice 2019; (215(1)):222-228 doi:10.1016/j.prp.2018.10.020.

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.

Sha C, Barrans S, Cucco F, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(3)):202-212 doi:10.1200/JCO.18.01314.

Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Hester LL, Park SI, Wood WA, et al.

Cancer 2019; (125(7)):1101-1112 doi:10.1002/cncr.31821.

Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.

He JS, Chen X, Wei GQ, et al.

Medicine 2019; (98(1)):e13741 doi:10.1097/MD.0000000000013741.

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Chihara D, Oki Y, Fanale MA, et al.

Annals of hematology 2019; (98(5)):1169-1176 doi:10.1007/s00277-018-3571-7.

Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.

Liu Y, Barta SK

American journal of hematology 2019; (94(5)):604-616 doi:10.1002/ajh.25460.

Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.

Abuamsha H, Kadri AN, Hernandez AV

Hematological oncology 2019; (37(3)):261-269 doi:10.1002/hon.2607.

Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.

Coutinho R, Lobato J, Esteves S, et al.

Annals of hematology 2019; (98(8)):1937-1946 doi:10.1007/s00277-019-03676-0.

Genetic alterations and their clinical implications in DLBCL.

Miao Y, Medeiros LJ, Li Y, et al.

Nature reviews. Clinical oncology 2019; (16(10)):634-652 doi:10.1038/s41571-019-0225-1.

Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge.

Gao D, Liu Z

Biomarker research 2019; (7()):11 doi:10.1186/s40364-019-0162-2.

Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements.

Alsharif R, Dunleavy K

Hematology/oncology clinics of North America 2019; (33(4)):587-596 doi:10.1016/j.hoc.2019.04.001.

Head and Neck Lymphoma in an Iranian Population.

Shamloo N, Ghannadan A, Jafari M, et al.

Iranian journal of otorhinolaryngology 2017; (29(94)):262-267.

Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.

Strongman H, Gadd S, Matthews A, et al.

Lancet (London, England) 2019; (394(10203)):1041-1054 doi:10.1016/S0140-6736(19)31674-5.

The application of antigen receptor gene rearrangement of BIOMED-2 in the pathologic diagnosis of 348 cases with non-Hodgkin lymphoma in a single institution in Southwest of China.

Liu X, He H, Li Y, et al.

Pathology, research and practice 2019; (215(11)):152615 doi:10.1016/j.prp.2019.152615.

[Diffuse large B-cell lymphoma: standard treatment and research questions].

Ohmachi K

[Rinsho ketsueki] The Japanese journal of clinical hematology 2019; (60(9)):1193-1198 doi:10.11406/rinketsu.60.1193.

Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.

McCarten KM, Nadel HR, Shulkin BL, Cho SY

Pediatric radiology 2019; (49(11)):1545-1564 doi:10.1007/s00247-019-04529-8.

Lymphoma of the female genital tract: a clinicopatholngical analysis of 25 cases.

Wang J, Zeng L, Chen S, et al.

American journal of translational research 2019; (11(9)):5800-5811.

Spontaneous resolution of untreated diffuse large B-cell lymphoma of maxillary bone after incisional biopsy.

Flatow-Trujillo L, Win K, Jencks A, et al.

Clinical case reports 2019; (7(11)):2082-2086 doi:10.1002/ccr3.2408.

A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

Makita S, Maruyama D, Maeshima AM, et al.

Asia-Pacific journal of clinical oncology 2020; (16(3)):108-114 doi:10.1111/ajco.13248.

Follicular lymphoma: 2020 update on diagnosis and management.

Freedman A, Jacobsen E

American journal of hematology 2020; (95(3)):316-327 doi:10.1002/ajh.25696.

Performance of Positron Emission Tomography-Computed Tomography and Bone Marrow Biopsy in Detecting Bone Marrow Infiltration in Lymphoma Cases

Büyükşimşek M, Kolsuz İ, Yetişir AE, et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology 2020; (37(4)):220-225 doi:10.4274/tjh.galenos.2020.2019.0361.

Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.

Linschoten M, Kamphuis JAM, van Rhenen A, et al.

The Lancet. Haematology 2020; (7(4)):e295-e308 doi:10.1016/S2352-3026(20)30031-4.

Anxiety prevalence in lymphoma: A systematic review and meta-analysis.

Vargas-Román K, Díaz-Rodríguez CL, Cañadas-De la Fuente GA, et al.

Health psychology : official journal of the Division of Health Psychology, American Psychological Association 2020; (39(7)):580-588 doi:10.1037/hea0000869.

Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group.

Moser O, Zimmermann M, Meyer U, et al.

Haematologica 2021; (106(5)):1390-1400 doi:10.3324/haematol.2019.244780.

Non-diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases.

Maeshima AM, Taniguchi H, Ida H, et al.

Human pathology 2020; (102()):33-43 doi:10.1016/j.humpath.2020.06.001.

Genetic and epigenetic determinants of diffuse large B-cell lymphoma.

Bakhshi TJ, Georgel PT

Blood cancer journal 2020; (10(12)):123 doi:10.1038/s41408-020-00389-w.

Acquired hemophilia A and delta storage pool deficiency in a patient with indolent non-Hodgkin lymphoma.

Rossio R, Cassin R, Lecchi A, et al.

Platelets 2022; (33(1)):168-170 doi:10.1080/09537104.2020.1869928.

Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment.

van Doesum JA, Niezink AGH, Huls GA, et al.

HemaSphere 2021; (5(2)):e523 doi:10.1097/HS9.0000000000000523.

Erectile dysfunction in male lymphoma survivors in a Southeast Asian country.

Gan GG, Ching Ng DL, Leong YC

Singapore medical journal 2022; (63(7)):376-380 doi:10.11622/smedj.2021003.

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.

Mitobe M, Kawamoto K, Suzuki T, et al.

Journal of clinical and experimental hematopathology : JCEH 2021; (61(1)):42-47 doi:10.3960/jslrt.20043.

Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.

Frood R, Burton C, Tsoumpas C, et al.

European journal of nuclear medicine and molecular imaging 2021; (48(10)):3198-3220 doi:10.1007/s00259-021-05233-2.

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Zhao P, Zhu L, Li L, et al.

Oncology letters 2021; (21(3)):218 doi:10.3892/ol.2021.12479.

Diffuse Large B-Cell Lymphoma.

Sehn LH, Salles G

The New England journal of medicine 2021; (384(9)):842-858 doi:10.1056/NEJMra2027612.

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma.

Candelaria M, Dueñas-Gonzalez A

Therapeutic advances in hematology 2021; (12()):2040620721989579 doi:10.1177/2040620721989579.

Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.

Barbosa MF, Fusco DR, Gaiolla RD, et al.

BMC cardiovascular disorders 2021; (21(1)):170 doi:10.1186/s12872-021-01996-6.

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.

Kaddu-Mulindwa D, Altmann B, Held G, et al.

European journal of nuclear medicine and molecular imaging 2021; (48(11)):3550-3559 doi:10.1007/s00259-021-05348-6.

Letter to the Editor: Fine-needle aspiration cytology and core-needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement.

Al-Abbadi M, Barroca H, Bode-Lesniewska B, et al.

European journal of haematology 2021; (107(2)):295-296 doi:10.1111/ejh.13646.

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.

Boddicker NJ, Larson MC, Castellino A, et al.

American journal of hematology 2021; (96(8)):979-988 doi:10.1002/ajh.26230.

Image-guided lymph node fine-needle aspiration: the Johns Hopkins Hospital experience.

Shyu S, Rajgariah A, Saoud C, et al.

Journal of the American Society of Cytopathology 2021; (10(6)):543-557 doi:10.1016/j.jasc.2021.04.004.

Oral and oropharyngeal lymphomas: A multi-institutional collaborative study.

de Arruda JAA, Schuch LF, Conte Neto N, et al.

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2021; (50(6)):603-612 doi:10.1111/jop.13211.

The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.

Wullenkord R, Berning P, Niemann AL, et al.

Annals of hematology 2021; (100(11)):2733-2744 doi:10.1007/s00277-021-04650-5.

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

Schuster SJ, Tam CS, Borchmann P, et al.

The Lancet. Oncology 2021; (22(10)):1403-1415 doi:10.1016/S1470-2045(21)00375-2.

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

Shadman M, Pasquini M, Ahn KW, et al.

Blood 2022; (139(9)):1330-1339 doi:10.1182/blood.2021013289.

Persistent fatigue among long-term non-Hodgkin lymphoma survivors.

LeBlanc MR, Zimmerman S, LeBlanc TW, et al.

Leukemia & lymphoma 2022; (63(2)):344-352 doi:10.1080/10428194.2021.1984450.

Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990-2019: Results From the Global Burden of Disease Study 2019.

Cai W, Zeng Q, Zhang X, Ruan W

Frontiers in medicine 2021; (8()):738693 doi:10.3389/fmed.2021.738693.

Burden of depression and anxiety disorders per disease codes in patients with lymphoma in Germany.

Tilch MK, Galle PR, Schattenberg JM, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(3)):2387-2395 doi:10.1007/s00520-021-06677-w.

How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.

Cabeçadas J, Nava VE, Ascensao JL, Gomes da Silva M

Current oncology (Toronto, Ont.) 2021; (28(6)):4611-4633 doi:10.3390/curroncol28060390.

Cytological Diagnosis of Aggressive Small-Cell Lymphomas.

Caputo A, Ciliberti V, Zeppa P, D'Antonio A

Acta cytologica 2022; (66(4)):269-278 doi:10.1159/000524270.

Immune targeted therapy for diffuse large B cell lymphoma.

Zheng Y, Si J, Yuan T, et al.

Blood science (Baltimore, Md.) 2021; (3(4)):136-148 doi:10.1097/BS9.0000000000000095.

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.

Singh A, Asghar I, Kohler L, et al.

Mediterranean journal of hematology and infectious diseases 2022; (14(1)):e2022018 doi:10.4084/MJHID.2022.018.

A Favorable Outcome of Grade 3 Follicular Lymphoma Treated With Surgery and Obinutuzumab Combined With Chemotherapy: A Case Report and Literature Review.

Mekheal E, Kania BE, Roman S, et al.

Cureus 2022; (14(3)):e23595 doi:10.7759/cureus.23595.

Primary non-Hodgkin lymphoma of the extra-hepatic bile duct: A case report.

Pararas N, Foukas PG, Pikoulis A, et al.

Molecular and clinical oncology 2022; (17(1)):115 doi:10.3892/mco.2022.2548.

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?

Chung C

Blood and lymphatic cancer : targets and therapy 2022; (12()):99-106 doi:10.2147/BLCTT.S282247.

Tackling Mantle Cell Lymphoma in Europe.

Horgan D, Walewski J, Aurer I, et al.

Healthcare (Basel, Switzerland) 2022; (10(9)) doi:10.3390/healthcare10091682.

Rituximab combined with GDP regimen can effectively improve the efficacy and immune function of non-Hodgkin lymphoma.

Song C, Feng Y, Ge F, et al.

American journal of translational research 2022; (14(9)):6313-6322.

Interim FDG-PET/CT for Response Assessment of Lymphoma.

Zeman MN, Akin EA, Merryman RW, Jacene HA

Seminars in nuclear medicine 2023; (53(3)):371-388 doi:10.1053/j.semnuclmed.2022.10.004.

PET/CT in Non-Hodgkin Lymphoma: An Update.

Zanoni L, Bezzi D, Nanni C, et al.

Seminars in nuclear medicine 2023; (53(3)):320-351 doi:10.1053/j.semnuclmed.2022.11.001.

[Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases].

Su Q, Peng X, Zhou CX, Yu GY

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2023; (55(1)):13-21.

CAR-T Cell Therapy: the Efficacy and Toxicity Balance.

Chohan KL, Siegler EL, Kenderian SS

Current hematologic malignancy reports 2023; (18(2)):9-18 doi:10.1007/s11899-023-00687-7.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

Dunsmore VJ, Neupert SD

Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

EBV and Lymphomagenesis.

Sausen DG, Basith A, Muqeemuddin S

Cancers 2023; (15(7)) doi:10.3390/cancers15072133.

Sexual dysfunction is highly prevalent in male survivors of malignant lymphoma.

Micas Pedersen S, Nielsen TH, Gang AO, et al.

Sexual medicine 2023; (11(2)):qfad021 doi:10.1093/sexmed/qfad021.

Patient perspectives of 'Watch and Wait' for chronic haematological cancers: Findings from a qualitative study.

McCaughan D, Roman E, Sheridan R, et al.

European journal of oncology nursing : the official journal of European Oncology Nursing Society 2023; (65()):102349 doi:10.1016/j.ejon.2023.102349.

Novel target and treatment agents for natural killer/T-cell lymphoma.

Tian XP, Cao Y, Cai J, et al.

Journal of hematology & oncology 2023; (16(1)):78 doi:10.1186/s13045-023-01483-9.

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.

Zelenetz AD, Gordon LI, Abramson JS, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(11)):1118-1131 doi:10.6004/jnccn.2023.0057.

Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies.

Crassini K, Gibson J

Internal medicine journal 2024; (54(1)):16-25 doi:10.1111/imj.16279.

Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.

Ong SY, Zain JM

American journal of hematology 2024; (99(3)):439-456 doi:10.1002/ajh.27165.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Financial toxicity and its influencing factors in patients with non-Hodgkin lymphoma: A cross-sectional study.

Li T, Cui P, Shao M, et al.

European journal of oncology nursing : the official journal of European Oncology Nursing Society 2024; (70()):102619 doi:10.1016/j.ejon.2024.102619.

CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies.

Castaneda Puglianini O, Chavez JC

Seminars in hematology 2024; (61(5)):290-296 doi:10.1053/j.seminhematol.2024.08.005.

Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas.

Gajzer D, Glynn E, Wu D, Fromm JR

Methods in molecular biology (Clifton, N.J.) 2025; (2865()):31-59 doi:10.1007/978-1-0716-4188-0_2.

Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations.

Varon B, Horowitz NA, Khatib H

Patient preference and adherence 2024; (18()):2159-2167 doi:10.2147/PPA.S485838.

Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives.

Caridà G, Martino EA, Bruzzese A, et al.

European journal of haematology 2025; (114(5)):775-784 doi:10.1111/ejh.14401.

Magnetic Resonance Imaging and [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Guided Therapy Improves Survival in Upper Aerodigestive Tract NK/T-Cell Lymphoma, Nasal Type: A Prospective Cohort Study.

Ren Q, Cui Y, Huang H, et al.

Head & neck 2025; (47(9)):2392-2400 doi:10.1002/hed.28137.

Case Report: Epididymal NK/T-cell lymphoma and adrenal diffuse large B-cell lymphoma are misdiagnosed as tuberculosis: two case reports and literature review.

Ye D, Liu X, Yang Y, et al.

Frontiers in oncology 2025; (15()):1529049 doi:10.3389/fonc.2025.1529049.

Prospective Assessment of Bone Marrow Involvement with Positron Emission Tomography vs Bone Marrow Biopsy in Patients with Lymphoma.

Singla S, Batra S, Dougall P, et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2025; (41(3)):650-655 doi:10.1007/s12288-024-01869-w.

Chimeric antigen receptor T-cell therapy and bispecific antibodies in the treatment of lymphoma for human immunodeficiency virus-infected patients: A systematic review.

Viera Plasencia A, I Purow J, Steger J, et al.

SAGE open medicine 2025; (13()):20503121251374954 doi:10.1177/20503121251374954.

Clinical characteristics and short-term outcomes of pediatric lymphoma: a retrospective cohort study from a large tertiary hospital in a low- and middle-income country.

Abuhalima D, Malhis D, Qadi Z, et al.

Scientific reports 2025; (15(1)):33057 doi:10.1038/s41598-025-11278-2.

Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.

Damaj G, de Masson A, Dreger P, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2025; doi:10.1111/jdv.70042.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Flow Cytometry as an Adjunct to Fine Needle Aspiration Cytology in the Diagnosis and Subtyping of Non-Hodgkin Lymphoma.

Kushwaha P, Jain SL, Gupta R, et al.

Cytopathology : official journal of the British Society for Clinical Cytology 2026; (37(2)):130-139 doi:10.1111/cyt.70046.